NIAAA Medications Development Clinical Investigations Network for the Treatment of Alcohol Use Disorder

NIAAA 治疗酒精使用障碍药物开发临床研究网络

• 批准号: 10506094
• 负责人: LARA RAY
• 金额: $ 40.01万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-17 至 2022-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10506094
• 关键词: Alcohol abuse; Clinical Trials; Clinical Trials Network; Contracts; Development; Dose; Drug Kinetics; Laboratory Study; Molecular Target; National Institute on Alcohol Abuse and Alcoholism; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Regimen; Reporting; Safety; Services; Testing; United States Food and Drug Administration; alcohol abuse therapy; alcohol cue; alcohol use disorder; clinical development; clinical investigation; clinical research site; efficacy clinical trial; programs

Medications development is a high priority program at National Institute on Alcohol Abuse and Alcoholism (NIAAA). Currently, only three medications are approved by the Food and Drug Administration (FDA) for the treatment of alcohol problems. These medications have demonstrated small to moderate effect sizes in clinical trials and do not work for everyone. Thus, the search for new molecular targets and more efficacious pharmacotherapies is critical. The purpose of the current contract is to support clinical research sites as part of a medications development clinical trials network for phase II clinical trials for the treatment of alcohol use disorder.

药物开发是国家酒精滥用和酒精中毒研究所 (NIAAA) 的一项高度优先计划。目前，只有三种药物获得美国食品和药物管理局 (FDA) 批准用于治疗酒精问题。这些药物在临床试验中显示出小到中等的效果，并且并不适合所有人。 因此，寻找新的分子靶点和更有效的药物疗法至关重要。 当前合同的目的是支持临床研究场所，作为治疗酒精使用障碍的 II 期临床试验的药物开发临床试验网络的一部分。